Apellis Pharmaceuticals, INC Form 4 insider transactions

Apellis Pharmaceuticals, Inc. CEO and Director Cedric Francois was granted 287,500 stock options with an exercise price of $19.39, vesting over two years.

Apellis Pharmaceuticals, Inc.'s Chief Financial Officer, Timothy Eugene Sullivan, was granted 82,500 stock options with an exercise price of $19.39, vesting over a two-year period.

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, was granted 82,500 stock options with a $19.39 exercise price, vesting over two years.

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, was granted 82,500 stock options at an exercise price of $19.39, vesting over two years.

Apellis Pharmaceuticals, Inc. has granted 11,250 stock options to James George Chopas, VP/Chief Accounting Officer, with an exercise price of $19.39, vesting over two years.

Apellis Pharmaceuticals, Inc. has granted 82,500 stock options to its Chief Business & Strategic Officer, Mark DeLong, at an exercise price of $19.39, with a two-year vesting schedule.

Apellis Pharmaceuticals, Inc. has reported the grant of restricted stock units and stock options to its Chief People Officer, Kelley Boucher, as part of standard executive compensation.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options on May 21, 2025, acquiring 12,780 shares of common stock.

Director Craig Wheeler reports the acquisition of 16,483 shares of common stock and 28,195 stock options in Apellis Pharmaceuticals on April 17, 2025.

James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, sold 183 shares of common stock on March 17, 2025, to cover tax withholding obligations.

David O. Watson, General Counsel of Apellis Pharmaceuticals, reported the transfer and sale of company stock, including transactions involving trusts and custodial accounts.

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 363 shares of common stock to cover tax withholding on restricted stock units.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 695 shares of common stock to cover tax obligations related to restricted stock units.

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 695 shares of common stock to cover tax withholding obligations related to restricted stock units.

Apellis Pharmaceuticals' Chief Financial Officer, Timothy Eugene Sullivan, sold 546 shares of common stock to cover tax obligations related to restricted stock units.

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold 825 shares of common stock to cover tax obligations related to released Restricted Stock Units.

Karen Lewis, Chief People Officer at Apellis Pharmaceuticals, sold 364 shares of common stock to cover tax withholding obligations related to restricted stock units.

Apellis Pharmaceuticals' Chief Development Officer, Jeffrey Eisele, sold 278 shares of common stock to cover tax obligations related to released Restricted Stock Units.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 826 shares of common stock to cover tax withholding obligations related to released Restricted Stock Units.

Apellis Pharmaceuticals CEO, Cedric Francois, sold 2,824 shares of common stock to cover tax obligations related to released Restricted Stock Units.

Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals, sold 365 shares of common stock to cover tax obligations related to restricted stock units.

David Watson, General Counsel of Apellis Pharmaceuticals, reports the sale of shares to cover tax withholding and details indirect ownership through custodial and trust accounts.

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 3,323 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Timothy Eugene Sullivan, CFO of Apellis Pharmaceuticals, sold 3,088 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold 3,948 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, sold 1,751 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

CEO Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals to cover tax obligations related to released Restricted Stock Units.

Jeffrey Eisele, Chief Development Officer of Apellis Pharmaceuticals, sold 1,291 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 3,948 shares of common stock on January 22, 2025, to cover tax obligations related to released Restricted Stock Units.

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,396 shares of common stock on January 22, 2025, to cover tax withholding related to released Restricted Stock Units.